Background and Purpose— Recombinant tissue plasminogen activator (rtPA) is an effective
treatment for acute ischemic stroke but is associated with an increased risk of intracranial …

Background Randomised trials have shown that alteplase improves the odds of a good
outcome when delivered within 4·5 h of acute ischaemic stroke. However, alteplase also …

… Zoe Morris, senior clinical fellow in neuroradiology,1 William N Whiteley, CSO clinical
academic fellow,1 WT Longstreth Jr, professor of neurology and epidemiology,2 Frank Weber, …

Background: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
induces a prothrombotic state, but long-term effects of COVID-19 on incidence of vascular …

Background Many international guidelines on the prevention of venous thromboembolism
recommend targeting heparin treatment at patients with stroke who have a high risk of venous …

Introduction— Endovascular thrombectomy is a highly efficacious treatment for large vessel
occlusion (LVO). LVO prediction instruments, based on stroke signs and symptoms, have …

Background— Thrombolytic therapy with intravenous alteplase within 4.5 hours of ischemic
stroke onset increases the overall likelihood of an excellent outcome (no, or nondisabling, …

Background and Purpose— Anxiety after stroke is common and disabling. Stroke trialists
have treated anxiety as a homogenous condition, and intervention studies have followed suit, …

… and statistical quality by comparing our results with those reported by Whiteley et al. … In line
with Whiteley et al, 4 we suggest that prognostic factor studies in IS should adjust for severity …

Background Updatable estimates of COVID-19 onset, progression, and trajectories underpin
pandemic mitigation efforts. To identify and characterise disease trajectories, we aimed to …